Who are aglatimagene besadenovec + valacyclovir's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Zopapogene imadenovec (Zopa).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/aglatimagene-besadenovec-valacyclovir.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

aglatimagene besadenovec + valacyclovir — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

aglatimagene besadenovec + valacyclovir (aglatimagene besadenovec + valacyclovir) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Oncolytic immunotherapy. Area: Oncology.

phase 3 Oncolytic immunotherapy IL-12 expression; adenovirus replication machinery Oncology Biologic Live · refreshed every 30 min

Target snapshot

aglatimagene besadenovec + valacyclovir (aglatimagene besadenovec + valacyclovir) — Candel Therapeutics, Inc.. Aglatimagene besadenovec is an oncolytic adenovirus expressing IL-12 that replicates in tumor cells and triggers immune activation, combined with valacyclovir (an antiviral) to modulate viral replication kinetics.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
aglatimagene besadenovec + valacyclovir TARGET	aglatimagene besadenovec + valacyclovir	Candel Therapeutics, Inc.	phase 3	Oncolytic immunotherapy	IL-12 expression; adenovirus replication machinery
Zopapogene imadenovec (Zopa)	Zopapogene imadenovec (Zopa)	Precigen, Inc	marketed	Oncolytic immunotherapy	Tumor cells (non-selective replication); immunostimulatory transgene product

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Oncolytic immunotherapy class)

Candel Therapeutics, Inc. · 1 drug in this class
Precigen, Inc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). aglatimagene besadenovec + valacyclovir — Competitive Intelligence Brief. https://druglandscape.com/ci/aglatimagene-besadenovec-valacyclovir. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab